COLL vs. ACAD, MRUS, ACLX, SWTX, RNA, RARE, PTGX, AAPG, SRRK, and MLTX
Should you be buying Collegium Pharmaceutical stock or one of its competitors? The main competitors of Collegium Pharmaceutical include ACADIA Pharmaceuticals (ACAD), Merus (MRUS), Arcellx (ACLX), SpringWorks Therapeutics (SWTX), Avidity Biosciences (RNA), Ultragenyx Pharmaceutical (RARE), Protagonist Therapeutics (PTGX), Ascentage Pharma Group International (AAPG), Scholar Rock (SRRK), and MoonLake Immunotherapeutics (MLTX). These companies are all part of the "pharmaceutical products" industry.
Collegium Pharmaceutical vs. Its Competitors
Collegium Pharmaceutical (NASDAQ:COLL) and ACADIA Pharmaceuticals (NASDAQ:ACAD) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, media sentiment, earnings, valuation, institutional ownership, risk and dividends.
In the previous week, Collegium Pharmaceutical had 5 more articles in the media than ACADIA Pharmaceuticals. MarketBeat recorded 11 mentions for Collegium Pharmaceutical and 6 mentions for ACADIA Pharmaceuticals. Collegium Pharmaceutical's average media sentiment score of 0.88 beat ACADIA Pharmaceuticals' score of 0.78 indicating that Collegium Pharmaceutical is being referred to more favorably in the media.
Collegium Pharmaceutical has a beta of 0.64, indicating that its stock price is 36% less volatile than the S&P 500. Comparatively, ACADIA Pharmaceuticals has a beta of 0.64, indicating that its stock price is 36% less volatile than the S&P 500.
ACADIA Pharmaceuticals has a net margin of 22.97% compared to Collegium Pharmaceutical's net margin of 6.61%. Collegium Pharmaceutical's return on equity of 99.08% beat ACADIA Pharmaceuticals' return on equity.
ACADIA Pharmaceuticals has higher revenue and earnings than Collegium Pharmaceutical. ACADIA Pharmaceuticals is trading at a lower price-to-earnings ratio than Collegium Pharmaceutical, indicating that it is currently the more affordable of the two stocks.
96.7% of ACADIA Pharmaceuticals shares are owned by institutional investors. 2.5% of Collegium Pharmaceutical shares are owned by company insiders. Comparatively, 28.3% of ACADIA Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Collegium Pharmaceutical presently has a consensus target price of $43.75, suggesting a potential upside of 38.58%. ACADIA Pharmaceuticals has a consensus target price of $27.88, suggesting a potential upside of 32.61%. Given Collegium Pharmaceutical's stronger consensus rating and higher possible upside, analysts plainly believe Collegium Pharmaceutical is more favorable than ACADIA Pharmaceuticals.
Summary
ACADIA Pharmaceuticals beats Collegium Pharmaceutical on 9 of the 16 factors compared between the two stocks.
Get Collegium Pharmaceutical News Delivered to You Automatically
Sign up to receive the latest news and ratings for COLL and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding COLL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Collegium Pharmaceutical Competitors List
Related Companies and Tools
This page (NASDAQ:COLL) was last updated on 7/9/2025 by MarketBeat.com Staff
Free COLL Stock Alerts